Rapid emergence of blaCTX-M among Enterobacteriaceae in U.S. Medical Centers: molecular evaluation from the MYSTIC Program (2007)

Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease
Mariana CastanheiraRonald N Jones

Abstract

A total of 220 gram-negative isolates showing distinct beta-lactam resistance profiles recovered in U.S. medical centers during the MYSTIC Program 2007 were evaluated to determine the presence of selected beta-lactamase genes. CTX-M-encoding genes, considered rare in the United States, were detected in 38.8% (28/70; three species) of the extended spectrum beta-lactamase-positive isolates and were observed in 80.0% of the participating hospitals. CTX-M-14 and -15 were found in multiple institutions (eight and nine medical centers, respectively), and CTX-M-3 was detected in only one isolate. The OXA-2 and -10 were identified in nine Enterobacteriaceae strains, and plasmid-mediated AmpC enzymes CMY-2 and FOX-5 were identified in six and four isolates, respectively, displaying negative clavulanate inhibition. Genes encoding OXA-23 and -24 were detected in 30.0% (15/50) of carbapenem-resistant Acinetobacter spp. strains. Retrospective sampling showed that these OXA enzymes were present since 2004 in the MYSTIC Program isolates. The KPC serine carbapenemases were observed in the majority of the carbapenem-resistant Enterobacteriaceae (usually Klebsiella pneumoniae), confirming an epidemic problem in the New York City area. The associ...Continue Reading

References

Apr 11, 2001·Emerging Infectious Diseases·K S Thomson
May 31, 2002·Journal of Clinical Microbiology·F Javier Pérez-Pérez, Nancy D Hanson
Apr 16, 2005·Clinical Microbiology Reviews·Timothy R WalshPatrice Nordmann
Aug 30, 2005·Current Opinion in Microbiology·Jodi M Thomson, Robert A Bonomo
Nov 4, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Gian Maria Rossolini
Nov 18, 2005·The Journal of Antimicrobial Chemotherapy·C EckertG Arlet
Mar 28, 2006·International Journal of Antimicrobial Agents·Neil WoodfordDavid M Livermore
Mar 30, 2006·Antimicrobial Agents and Chemotherapy·George A JacobyDavid C Hooper
Jun 1, 2006·The American Journal of Medicine·David L Paterson
Jul 28, 2006·Antimicrobial Agents and Chemotherapy·A RobicsekD C Hooper
Aug 31, 2006·Antimicrobial Agents and Chemotherapy·Karen LolansJohn P Quinn
Sep 1, 2006·Current Opinion in Microbiology·Rafael Cantón, Teresa M Coque
Sep 5, 2006·Diagnostic Microbiology and Infectious Disease·Paul R Rhomberg, Ronald N Jones
Sep 30, 2006·The Lancet Infectious Diseases·Ari RobicsekDavid C Hooper
Dec 13, 2006·The Journal of Antimicrobial Chemotherapy·David M LivermoreNeil Woodford
Jan 16, 2007·Antimicrobial Agents and Chemotherapy·Mariana CastanheiraAna C Gales
Oct 12, 2007·Future Microbiology·Laurent PoirelPatrice Nordmann
Jan 25, 2008·Emerging Infectious Diseases·Yohei DoiDavid L Paterson

❮ Previous
Next ❯

Citations

Mar 3, 2010·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Mariana CastanheiraRonald N Jones
Jan 8, 2013·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Maria Sjölund-KarlssonJean M Whichard
Aug 19, 2009·The Journal of Antimicrobial Chemotherapy·Peter M Hawkey, Annie M Jones
Aug 8, 2012·The Journal of Antimicrobial Chemotherapy·Laura Garcia-AlvarezPeter Hawkey
Sep 30, 2009·Antimicrobial Agents and Chemotherapy·Aránzazu ValverdeTeresa M Coque
May 1, 2013·Antimicrobial Agents and Chemotherapy·Brian VanScoyPaul G Ambrose
Oct 14, 2009·Clinical Microbiology Reviews·Jacob StrahilevitzAri Robicsek
Apr 13, 2011·Clinical Microbiology Reviews·Thomas F O'Brien, John Stelling
Jul 10, 2009·Journal of Clinical Microbiology·Shannon E McGettiganPaul H Edelstein
Dec 25, 2009·Journal of Clinical Microbiology·Jennifer LeRonald N Jones
Jul 3, 2010·Critical Care : the Official Journal of the Critical Care Forum·Karen Bush
Jan 5, 2011·Emerging Infectious Diseases·Maria Sjölund-KarlssonJean M Whichard
Nov 6, 2013·Emerging Infectious Diseases·Guiqing WangGary P Wormser
Nov 16, 2013·The Journal of Antimicrobial Chemotherapy·Krisztina M Papp-WallaceRobert A Bonomo
Feb 26, 2011·Current Microbiology·Maíra Espíndola Silva de MeloAna Catarina de Souza Lopes
Nov 12, 2013·International Journal of Food Microbiology·Hetty BlaakAna Maria de Roda Husman
Nov 9, 2012·Expert Review of Respiratory Medicine·Philip E GrgurichDonald E Craven
Feb 12, 2013·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Salome N SeiffertAndrea Endimiani
Oct 5, 2010·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·José Manuel Rodríguez-MartínezAlvaro Pascual
May 18, 2010·Diagnostic Microbiology and Infectious Disease·Coralia N MihuKenneth V Rolston
Jan 12, 2010·International Journal of Antimicrobial Agents·Gisele Peirano, Johann D D Pitout
Sep 1, 2009·Current Opinion in Microbiology·Louis B Rice
Nov 21, 2015·Jundishapur Journal of Microbiology·Hasan AfzaliMohammad Zibaei
Sep 29, 2011·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·Z A QureshiY Doi
Aug 28, 2018·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Daniel A TadesseShaohua Zhao
Apr 26, 2015·Applied and Environmental Microbiology·Margaret A DavisThomas E Besser
Oct 29, 2013·Applied and Environmental Microbiology·Hetty BlaakFranciska M Schets

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Related Papers

Current Opinion in Microbiology
Rafael Cantón, Teresa M Coque
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
K Bush
© 2022 Meta ULC. All rights reserved